Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cluster randomised trial of low molecular weight heparins - Directly through Epic
2022-502402-32-00Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in venous thromboembolism (VTE) comparing Tinzaparin with Dalteparin (2 arms). Primary endpoint: Major bleeding requiring blood transfusion and all-cause mortality at 30 days. Started Jan 2023; status: completed.
02
Drugs
tinzaparindalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2022-502402-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502402-32-00.